MOESM1 of Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINAÂŽ): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

Additional file 1. Full inclusion and exclusion criteria for CARMELINAÂŽ.